Analysts Issue Forecasts for Edwards Lifesciences Co.'s Q1 2025 Earnings (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Leerink Partnrs dropped their Q1 2025 earnings estimates for Edwards Lifesciences in a research report issued to clients and investors on Wednesday, April 17th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will post earnings of $0.74 per share for the quarter, down from their prior estimate of $0.75. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.76 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' Q2 2025 earnings at $0.78 EPS, Q3 2025 earnings at $0.79 EPS and Q4 2025 earnings at $0.80 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting analysts' consensus estimates of $0.64. The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. Edwards Lifesciences's revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.64 EPS.

Several other equities research analysts also recently weighed in on the stock. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the company a "hold" rating in a research note on Wednesday, February 7th. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an "overweight" rating in a research report on Thursday, March 21st. Evercore ISI lifted their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an "in-line" rating in a report on Thursday, April 4th. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an "equal weight" rating to an "overweight" rating and set a $94.00 target price for the company in a research report on Friday, February 2nd. Finally, StockNews.com lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Wednesday, March 20th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus target price of $91.73.

Edwards Lifesciences Trading Down 0.9 %

Shares of EW stock traded down $0.79 during mid-day trading on Thursday, reaching $86.45. 3,121,938 shares of the stock traded hands, compared to its average volume of 3,865,237. The stock's fifty day simple moving average is $90.12 and its two-hundred day simple moving average is $78.14. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The company has a market cap of $52.04 billion, a price-to-earnings ratio of 37.93, a price-to-earnings-growth ratio of 4.46 and a beta of 1.05. Edwards Lifesciences has a 1-year low of $60.57 and a 1-year high of $96.12.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently modified their holdings of the stock. Castleview Partners LLC acquired a new position in Edwards Lifesciences during the first quarter worth $25,000. Riverview Trust Co purchased a new stake in Edwards Lifesciences during the 1st quarter worth approximately $34,000. DSM Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $28,000. Compass Wealth Management LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at $31,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $34,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares of the company's stock, valued at $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the company's stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total transaction of $156,030.70. Following the completion of the sale, the vice president now owns 17,213 shares in the company, valued at $1,566,038.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the company's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock worth $17,166,254 in the last quarter. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.